The New York Times | June 15, 2021
This view is not without its detractors. Some experts have argued that pharmaceutical companies are simply trying to protect their monopoly power by overstating manufacturing challenges and casting developing countries as insufficiently advanced to meet them — “an offensive and a racist notion,” Matthew Kavanagh, director of the Global Health Policy and Politics Initiative at Georgetown University, told The Times.
“We’re not talking about any immediate help for India or Latin America or other countries going through an enormous spread of the virus,” Lawrence Gostin, director of the O’Neill Institute for National and Global Health Law at Georgetown Law, told Stat. “While they’re going to be negotiating the text, the virus will be mutating.”